CoChat

Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy

Open access
Shraibman, Bracha, Kadosh, Dganit Melamed, Barnea, Eilon, Admon, Arie · 2016 · Molecular & Cellular Proteomics
Cited by 71

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Treatment of cancer cells with anticancer drugs often fails to achieve complete remission. Yet, such drug treatments may induce alteration in the tumor's gene expression patterns, including those of Cancer/Testis Antigens (CTA). The degradation products of such antigens can be presented as HLA peptides on the surface of the tumor cells and be developed into anticancer immunotherapeutics. For example, the DNA methyl transferase inhibitor, 5-aza-2'-deoxycytidine (Decitabine) has limited antitumor efficacy, yet it induces the expression of many genes, including CTAs that are normally silenced in the healthy adult tissues. In this study, the presentation of many new HLA peptides derived from CTAs and induced by Decitabine was demonstrated in three human Glioblastoma cell lines. Such presentation of CTA-derived HLA peptides can be exploited for development of new treatment modalities, combining drug treatment with anti-CTA targeted immunotherapy. The Decitabine-induced HLA peptidomes include many CTAs that are not normally detected in healthy tissues or in cancer cells, unless treated with the drug. In addition, the study included large-scale analyses of the simultaneous effects of Decitabine on the transcriptomes, proteomes and HLA peptidomes of the human Glioblastoma cells. It demonstrates the poor correlations between these three levels of gene expression, both in their total levels and in their response to the drug. The proteomics and HLA peptidomics data are available via ProteomeXchange with identifier PXD003790 and the transcriptomics data are available via GEO with identifier GSE80137.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/mcp.m116.060350

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 69

  1. Alifieris, 2015, Glioblastoma multiforme: Pathogenesis and treatment, Pharmacol. Ther, 152, 63, 10.1016/j.pharmthera.2015.05.005 · DOI · Paper page
  2. Mohme, 2014, Immunological challenges for peptide-based immunotherapy in glioblastoma, Cancer Treat. Rev, 40, 248, 10.1016/j.ctrv.2013.08.008 · DOI
  3. Weiss, 2015, Immunotherapy for glioblastoma: concepts and challenges, Curr. Opin. Neurol, 28, 639, 10.1097/WCO.0000000000000249 · DOI
  4. Galluzzi, 2014, Classification of current anticancer immunotherapies, Oncotarget, 5, 12472, 10.18632/oncotarget.2998 · DOI · Paper page
  5. Rammensee, 2013, HLA ligandome tumor antigen discovery for personalized vaccine approach, Expert Rev. Vaccines, 12, 1211, 10.1586/14760584.2013.836911 · DOI
  6. Pol, 2015, Trial Watch: Peptide-based anticancer vaccines, Oncoimmunology, 4, e974411, 10.4161/2162402X.2014.974411 · DOI · Paper page
  7. Comber, 2014, MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines, Therap. Adv. Vaccines, 2, 77, 10.1177/2051013614525375 · DOI · Paper page
  8. de Verteuil, 2012, Origin and plasticity of MHC I-associated self peptides, Autoimmunity Rev, 11, 627, 10.1016/j.autrev.2011.11.003 · DOI
  9. Granados, 2014, The nature of self for T cells-a systems-level perspective, Curr. Opin. Immunol, 34C, 1
  10. Heemskerk, 2013, The cancer antigenome, EMBO J, 32, 194, 10.1038/emboj.2012.333 · DOI · Paper page
  11. Cohen, 2015, Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes, J. Clin. Invest, 125, 3981, 10.1172/JCI82416 · DOI · Paper page
  12. Gubin, 2015, Tumor neoantigens: building a framework for personalized cancer immunotherapy, J. Clin. Invest, 125, 3413, 10.1172/JCI80008 · DOI · Paper page
  13. Schumacher, 2015, Neoantigens in cancer immunotherapy, Science, 348, 69, 10.1126/science.aaa4971 · DOI · Paper page
  14. Peper, 2015, A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy, Cancer Immunol. Immunother, 64, 1295, 10.1007/s00262-015-1682-8 · DOI
  15. Ilyas, 2015, Landscape of Tumor Antigens in T Cell Immunotherapy, J. Immunol, 195, 5117, 10.4049/jimmunol.1501657 · DOI · Paper page
  16. Hinrichs, 2013, Reassessing target antigens for adoptive T-cell therapy, Nat. Biotechnol, 31, 999, 10.1038/nbt.2725 · DOI · Paper page
  17. Chen, 1997, A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening, Proc. Natl. Acad. Sci. U.S.A, 94, 1914, 10.1073/pnas.94.5.1914 · DOI · Paper page
  18. Whitehurst, 2014, Cause and consequence of cancer/testis antigen activation in cancer, Annu. Rev. Pharmacol. Toxicol, 54, 251, 10.1146/annurev-pharmtox-011112-140326 · DOI · Paper page
  19. Cheng, 2011, Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis, Spermatogenesis, 1, 209, 10.4161/spmg.1.3.17990 · DOI
  20. Gjerstorff, 2015, Oncogenic cancer/testis antigens: prime candidates for immunotherapy, Oncotarget, 6, 15772, 10.18632/oncotarget.4694 · DOI · Paper page
  21. Weber, 1994, Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine, Cancer Res, 54, 1766
  22. De Smet, 1996, The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation, Proc. Natl. Acad. Sci. U.S.A, 93, 7149, 10.1073/pnas.93.14.7149 · DOI · Paper page
  23. Fratta, 2011, The biology of cancer testis antigens: putative function, regulation and therapeutic potential, Mol. Oncol, 5, 164, 10.1016/j.molonc.2011.02.001 · DOI · Paper page
  24. Feinberg, 1983, Hypomethylation distinguishes genes of some human cancers from their normal counterparts, Nature, 301, 89, 10.1038/301089a0 · DOI · Paper page
  25. Gama-Sosa, 1983, The 5-methylcytosine content of DNA from human tumors, Nucleic Acids Res, 11, 6883, 10.1093/nar/11.19.6883 · DOI · Paper page
  26. Heninger, 2015, Augmenting antitumor immune responses with epigenetic modifying agents, Front. Immunol, 6, 1
  27. Valdespino, 2015, (Potential of epigenetic therapies in the management of solid tumors, Cancer Manag. Res, 7, 241, 10.2147/CMAR.S70358 · DOI
  28. Claus, 2005, Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents, Semin. Oncol, 32, 511, 10.1053/j.seminoncol.2005.07.024 · DOI
  29. Everson, 2016, Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma, Neuro. Oncol, 18, 368, 10.1093/neuonc/nov153 · DOI
  30. Serrano, 2001, Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment, Int. J. Cancer, 94, 243, 10.1002/ijc.1452 · DOI · Paper page
  31. Coral, 1999, Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR), J. Immunother, 22, 16, 10.1097/00002371-199901000-00003 · DOI · Paper page
  32. Nie, 2001, DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas, Carcinogenesis, 22, 1615, 10.1093/carcin/22.10.1615 · DOI · Paper page
  33. Coral, 2012, Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications, Br. J. Cancer, 107, 1116, 10.1038/bjc.2012.361 · DOI
  34. Konkankit, 2011, Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway, J. Transl. Med, 9, 192, 10.1186/1479-5876-9-192 · DOI · Paper page
  35. Weiser, 2001, Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1, J. Immunother, 24, 151, 10.1097/00002371-200103000-00010 · DOI · Paper page
  36. Caron, 2015, Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry, Mol. Cell. Proteomics, 14, 3105, 10.1074/mcp.O115.052431 · DOI · Paper page
  37. Fortier, 2008, The MHC class I peptide repertoire is molded by the transcriptome, J. Exp. Med, 205, 595, 10.1084/jem.20071985 · DOI · Paper page
  38. de Verteuil, 2010, Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules, Mol. Cell. Proteomics, 9, 2034, 10.1074/mcp.M900566-MCP200 · DOI · Paper page
  39. Granados, 2012, MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements, Blood, 119, e181, 10.1182/blood-2012-02-412593 · DOI
  40. Weinzierl, 2007, Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface, Mol. Cell. Proteomics, 6, 102, 10.1074/mcp.M600310-MCP200 · DOI · Paper page
  41. Hoof, 2012, Proteome sampling by the HLA class I antigen processing pathway, PLoS Comput. Biol, 8, e1002517, 10.1371/journal.pcbi.1002517 · DOI
  42. Bassani-Sternberg, 2015, Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation, Mol. Cell. Proteomics, 14, 658, 10.1074/mcp.M114.042812 · DOI · Paper page
  43. Milner, 2013, The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome, Mol. Cell. Proteomics, 12, 1853, 10.1074/mcp.M112.026013 · DOI
  44. Ishihama, 2006, Modular stop and go extraction tips with stacked disks for parallel and multidimensional Peptide fractionation in proteomics, J. Proteome Res, 5, 988, 10.1021/pr050385q · DOI · Paper page
  45. Bourdetsky, 2014, The nature and extent of contributions by defective ribosome products to the HLA peptidome, Proc. Natl. Acad. Sci. U.S.A, 111, E1591, 10.1073/pnas.1321902111 · DOI
  46. Cox, 2008, MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification, Nat. Biotechnol, 26, 1367, 10.1038/nbt.1511 · DOI · Paper page
  47. Cox, 2011, Andromeda: a peptide search engine integrated into the MaxQuant environment, J. Proteome Res, 10, 1794, 10.1021/pr101065j · DOI · Paper page
  48. Vizcaino, 2016, 2016 update of the PRIDE database and its related tools, Nucleic Acids Res, 44, D447, 10.1093/nar/gkv1145 · DOI · Paper page
  49. Trapnell, 2009, TopHat: discovering splice junctions with RNA-Seq, Bioinformatics, 25, 1105, 10.1093/bioinformatics/btp120 · DOI · Paper page
  50. Anders, 2015, HTSeq–a Python framework to work with high-throughput sequencing data, Bioinformatics, 31, 166, 10.1093/bioinformatics/btu638 · DOI · Paper page
  51. Almeida, 2009, CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens, Nucleic Acids Res, 37, D816, 10.1093/nar/gkn673 · DOI · Paper page
  52. Andreatta, 2016, Gapped sequence alignment using artificial neural networks: application to the MHC class I system, Bioinformatics, 32, 511, 10.1093/bioinformatics/btv639 · DOI · Paper page
  53. Liu, 2016, The interdependence of transcript and protein abundance: new data-new complexities, Mol. Syst. Biol, 12, 856, 10.15252/msb.20156720 · DOI · Paper page
  54. Wu, 2016, BioGPS: building your own mash-up of gene annotations and expression profiles, Nucleic Acids Res, 44, D313, 10.1093/nar/gkv1104 · DOI · Paper page
  55. Wu, 2009, BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources, Genome Biol, 10, R130, 10.1186/gb-2009-10-11-r130 · DOI · Paper page
  56. Dutoit, 2002, Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting, J. Clin. Invest, 110, 1813, 10.1172/JCI16428 · DOI
  57. Marchand, 1999, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1, Int. J. Cancer, 80, 219, 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S · DOI · Paper page
  58. Rosenberg, 1998, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat. Med, 4, 321, 10.1038/nm0398-321 · DOI · Paper page
  59. Kalaora, 2016, Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens, Oncotarget, 7, 5110, 10.18632/oncotarget.6960 · DOI · Paper page
  60. Kanaseki, 2013, ERAAP and tapasin independently edit the amino and carboxyl termini of MHC class I peptides, J. Immunol, 191, 1547, 10.4049/jimmunol.1301043 · DOI
  61. Rist, 2013, HLA peptide length preferences control CD8+ T cell responses, J. Immunol, 191, 561, 10.4049/jimmunol.1300292 · DOI
  62. Li, 2015, Gene expression. Statistics requantitates the central dogma, Science, 347, 1066, 10.1126/science.aaa8332 · DOI · Paper page
  63. Wang, 2014, Leveraging the complementary nature of RNA-Seq and shotgun proteomics data, Proteomics, 14, 2676, 10.1002/pmic.201400184 · DOI
  64. Lange, 2008, Selected reaction monitoring for quantitative proteomics: a tutorial, Mol. Syst. Biol, 4, 222, 10.1038/msb.2008.61 · DOI · Paper page
  65. Lesur, 2015, Advances in high-resolution accurate mass spectrometry application to targeted proteomics, Proteomics, 15, 880, 10.1002/pmic.201400450 · DOI
  66. Admon, 2011, The Human Immunopeptidome Project, a suggestion for yet another postgenome next big thing, Mol. Cell. Proteomics, 10, 10.1074/mcp.O111.011833 · DOI
  67. Granados, 2014, Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides, Nat. Commun, 5, 3600, 10.1038/ncomms4600 · DOI
  68. Lundegaard, 2012, Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?, Expert Rev. Vaccines, 11, 43, 10.1586/erv.11.160 · DOI
  69. Yeung, 2013, LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma, Clin. Cancer Res, 19, 1816, 10.1158/1078-0432.CCR-12-2861 · DOI

Cited by

See all 71

Metadata

Authors
Shraibman, B., Kadosh, D. M., Barnea, E., & Admon, A.
Venue
Molecular & Cellular Proteomics
Publisher
Elsevier BV
Published
2016-09
Volume
15
Issue
9
Pages
3058-3070
ISSN
1535-9476 (ISSN-L)
OpenAlex
W2464113003
Cited by
71
References
7
FWCI
3.36
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
Seventh Framework Programme (GAPVAC)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy. https://app.cochat.ai/papers/10.1074/mcp.m116.060350
The paper
Shraibman, B., Kadosh, D. M., Barnea, E., & Admon, A. (2016). Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy. Molecular & Cellular Proteomics. https://doi.org/10.1074/mcp.m116.060350

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.